Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Immunotherapy. Medical University of South Carolina, Charleston, SC, United States



Survival: 21.5 months
   
Toxicity Grade: 5
   
Treatments: Immunotherapy
   
Drugs:
Country: United States
   
City/State/Province: Charleston, SC
   
Hospital: Medical University of South Carolina
   
Journal: Link
   
Date: 3/2015

Description:
Patients:
This phase 2 study involved 21 previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma patients. The median patient age was 63 years and 81% were male.

Treatment:
Patients received immunotherapy with ofatumumab (human anti-CD20 monoclonal antibody that directs immune system to attack cancer cells) and lenalidomide.

Toxicities:
There was one treatment-related death due to infection. Grade 4 neutropenia and thrombocytopenia, grade 3 tumor flare reaction, and grade 2 infusion related reaction and fatigue were also reported.

Results:
The median overall survival was 21.5 months.

Support:
This study was supported by GlaxoSmithKline.

Correspondence: Dr. Luciano J. Costa; email: costalj@musc.edu

E-mail to a Friend Email Physician More Information